Reports and Briefs on Genitourinary and Osteoporosis in United Kingdom

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
Report
Report

Forecast Insight: Fibromyalgia - Regulatory caution threatens EU market expansion

Provides analysis of key events and their impact on the fibromyalgia market over the last year (July 2008June 2009). Includes indication- and country-specific 10-year forecasts of key marketed, generic, and pipeline products to 2018.

Published By Datamonitor
03 Jun 2009 $15200
Buy
Report
Report

Pipeline Insight: Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

Overview of the current prostate cancer clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2018, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
14 Aug 2009 $11400
Buy
Report
Report

Commercial Insight: Hormonal Contraceptives - Look beyond oral contraception for a competitive edge

Full analysis of the current and future hormonal contraceptives drug market, with country-specific forecasts to 2018 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
02 Oct 2009 $15200
Buy
Report
Report

Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed

In-depth analysis of the endometriosis drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2018, and key opinion leader insight.

Published By Datamonitor
10 Dec 2009 $11400
Buy
Report
Report

Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues

Examination of the key issues in the treatment of sexual dysfunction, including risk factors, estimates of patient potential, overview of current and pipeline treatments, unmet needs, analysis of commercial opportunities and key stakeholder opinions.

Published By Datamonitor
04 Mar 2010 $7600
Buy
Report
Report

Stakeholder Opinions: Cervical and Endometrial Cancer - Opportunities remain outside the big gynecologic malignancies

Key issues in the gynecological malignancies market, focusing mainly on endometrial and cervical cancer, including forecast epidemiology, current treatment trends and controversies, unmet needs, insight into pipeline activity and stakeholder opinion.

Published By Datamonitor
17 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy

Key issues in the ovarian cancer market, including forecast epidemiology, current treatment trends and controversies, unmet needs, insight into pipeline activity and stakeholder opinion.

Published By Datamonitor
12 Jul 2010 $3800
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

In-depth analysis of the osteoporosis drug pipeline, including a review of clinical unmet needs, assessment of the clinical and commercial prospects of 12 key late-stage agents, sales forecasts to 2019 and key opinion leader insight.

Published By Datamonitor
21 Jul 2010 $11400
Buy
Report
Report

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

This report covers 4 STDs: chlamydia, gonorrhea, human papillomavirus (HPV), and herpes simplex virus type 2 (HSV-2). It discusses disease background, epidemiology, unmet needs as well as marketed and pipeline therapeutic and preventative strategies.

Published By Datamonitor
05 Aug 2010 $3800
Buy

« | 1 | 2 | 3 | » »|

No help is available.